Watson announced that it has received FDA approval on its Abbreviated New Drug Application for Tranexamic Acid Tablets, the generic version of Ferring‘s Lysteda. Lysteda is an antifibrinolytic indicated for cyclic heavy menstrual bleeding.

Tranexamic acid, a synthetic lysine amino acid derivative, diminishes the dissolution of hemostatic fibrin by plasmin. In the presence of tranexamic acid, the lysine receptor binding sites of plasmin for fibrin are occupied, preventing binding to fibrin monomers, thus preserving and stabilizing fibrin’s matrix structure.

Tranexamic Acid Tablets will be available in a 650mg dosage strength. Watson intends to begin shipping this product immediately.

For more information call (800) 272-5525 or visit www.watsonpharm.com.